Cancer NetworkOriginal article
<![CDATA[Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC]]>
Phase 1positiveIza-BrenPositive
AI Analysis
Summary
Phase 1b study data for izalontamab brengitecan (Iza-Bren) demonstrated a 48.1% objective response rate in previously treated extensive-stage small cell lung cancer patients, showing encouraging anti-tumor activity.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
48.1% objective response rate in previously treated extensive-stage SCLC
Importance:6/10
Sentiment:
0.75
oncologysmall cell lung cancerclinical trialPhase 1bobjective response rate
Read the original article
Published by Cancer Network on August 12, 2026 3:00 PM